Bristol Myers deploys Anthropic's Claude AI to accelerate drug discovery

Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery

The pharma giant is rolling out Claude across 30,000 employees, betting that generative AI can compress timelines from lab bench to pharmacy shelf.

Bristol Myers Squibb is handing Anthropic’s Claude AI to its entire workforce. The pharmaceutical company announced a partnership on May 20 to deploy Claude across more than 30,000 employees, targeting everything from early-stage research to manufacturing and commercial operations.

BMS isn’t just licensing a chatbot for its research team. The company plans to leverage Claude Code, Anthropic’s coding-focused AI tool, and evaluate its applications across research, drug development, manufacturing, and commercial affairs.

AbbVie, one of BMS’s major competitors, has already reported 40% to 60% time savings in document preparation workflows using Claude for Life Sciences.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery

The pharma giant is rolling out Claude across 30,000 employees, betting that generative AI can compress timelines from lab bench to pharmacy shelf.

by Editorial Team

May. 21, 2026

Add us on Google

AbbVie, one of BMS’s major competitors, has already reported 40% to 60% time savings in document preparation workflows using Claude for Life Sciences.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery

Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery

Get Crypto Briefing in your inbox